Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens
Autore:
Gutierrez-Delgado, F; Maloney, DG; Press, OW; Golden, J; Holmberg, LA; Maziarz, RT; Hooper, H; Buckner, CD; Appelbaum, FR; Bensinger, WI;
Indirizzi:
Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA Fred Hutchinson Canc Res Ctr Seattle WA USA 98109 , Seattle, WA 98109 USA Puget Sound Oncol Consortium, Seattle, WA USA Puget Sound Oncol Consortium Seattle WA USA Consortium, Seattle, WA USA
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 5, volume: 28, anno: 2001,
pagine: 455 - 461
SICI:
0268-3369(200109)28:5<455:ASCTFN>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; TOTAL-BODY IRRADIATION; HIGH-DOSE THERAPY; FOLLICULAR LYMPHOMA; MALIGNANT-LYMPHOMA; CYCLOPHOSPHAMIDE; ETOPOSIDE; CONSOLIDATION; ENGRAFTMENT; FAILURE;
Keywords:
high-dose chemotherapy; stem cell transplantation; lymphomas; busulfan; melphalan; thiotepa;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Bensinger, WI Fred Hutchinson Canc Res Ctr, 1100 Fairview Av N D5-390,POB 19024, Seattle, WA 98109 USA Fred Hutchinson Canc Res Ctr 1100 Fairview Av N D5-390,POB 19024 Seattle WA USA 98109
Citazione:
F. Gutierrez-Delgado et al., "Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens", BONE MAR TR, 28(5), 2001, pp. 455-461

Abstract

The aim of this study was to compare toxicity and efficacy of total body irradiation (TBI), cyclophosphamide (CY) and etoposide (E) (TBI/CY/E) vs busulfan, melphalan and thiotepa (Bu/Mel/T) in patients receiving autologous stem cell infusion (ASCI) for malignant lymphoma (NHL). Between September 1990 and July 1998, 351 patients with NHL were treated with TBI/CY/E (n = 221) or Bu/Mel/T (n = 130) followed by ASCI. Patients in first, or second remission, first responding or untreated relapse were defined as having less advanced disease before transplantation. The median follow-up was 5 years (range 1-9) and 3.5 years (1-6) for patients receiving TBI/CY/E and Bu/Mel/T, respectively. The cumulative probabilities of survival, event-free survival(EFS) and relapse at 5 years were 44%, 32%, 49% following TBI/CY/E and 42%, 34% and 42% following Bu/Mel/T. The probability of EFS at 5 years for patients who had prior dose-limiting radiation (n = 59) was 32% after Bu/Mel/Ttherapy. Transplant-related mortality was 16% for TBI/CY/E and 21% for Bu/Mel/Y. In univariate and multivariate analyses, more advanced disease status was associated with poor outcome (TBI/CY/E: RR 0.70, CI 0.50 to 0.97 P = 0.04; Bu/Mel/T: RR 0.61, CI 0.39 to 0.97 P = 0.03). No significant differences in toxicities and outcomes were observed between these two regimens despite the inclusion of patients who had received dose-limiting irradiation in the Bu/Mel/T regimen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 23:24:00